In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...

AbbVie (ABBV) announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the efficacy and safety of ELAHERE in women ...

HOUSE, PA — Third Arc Bio Inc. has administered the first dose of ARC101 to a patient in its inaugural first-in-human ...

SESAUA annual meeting featured a prostate cancer session and a presentation by Dr. Paul Sieber discussing a post hoc analysis ...

The EC approved the CAR T-cell therapy based on data from a Phase II study showing a 94 percent complete response rate.

BioCity Biopharmaceuticals and MSD have signed a clinical trial partnership agreement to assess BC3195 in conjunction with ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a wide | ...

An expert discusses how CheckMate 274 is a phase 3, randomized, double-blind trial evaluating adjuvant nivolumab vs placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after ...

Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...

announced on February 28 that a trial train arrived at Cuffe Parade, the final station of Mumbai's first underground Metro line, Metro Line 3 or Aqualine. This, MMRC said, this marks a crucial step ...

A tool-based approach can significantly aid in the harmonization of regulatory requirements, mitigate inadvertent risks, and ...

The strength of evidence is solid, supported by the multicenter phase II trial design, which included a substantial ... tumor size <2 cm but with high Ki-67 level or histologic grade 3. Clinical and ...